KYORIN Pharmaceutical Co Ltd: Segment Analysis

KYORIN Pharmaceutical Co Ltd (Kyorin), formerly Kyorin Holdings Inc, is a pharmaceutical company that offers prescription medicines, generic drugs, quasi-drugs, reagents, intermediates and other products. It also sells diagnostic products and industrial chemicals. Kyorin's business portfolio includes new drug discovery and development, new drug introduction, and new drug sales. The company is actively involved in infectious disease-related products, over-the-counter drugs, and generic drugs production.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company is focused on advancing drug discovery and development through innovative strategies and technologies. The company aims to contribute to public health by creating high-value new products that address medical needs. Kyorin is actively pursuing new drug discovery strategies, leveraging both internal core technologies in small molecule drug discovery and external technologies. The company is also committed to human resources development, enhancing researchers' specialization and broadening their perspectives to achieve its long-term vision, "Vision 110." Kyorin emphasizes ethical considerations in human and animal research, compliance with international guidelines, and transparency in clinical trials. The company is also focused on protecting intellectual property to maintain competitiveness and support business continuity. The company has a dedicated R&D structure focused on therapeutic areas to enrich the scope and improve the quality of research themes. The company also has internal committees responsible for ethical oversight in human and animal research, biotechnology, and intellectual property management. In FY2026, the company spent JPY12,060 million on its R&D activities, which, as a percentage of revenue, stood at 9.5%.